BR112013028776B1 - Pteroestilbeno para uso no alívio ou prevenção da ansiedade - Google Patents

Pteroestilbeno para uso no alívio ou prevenção da ansiedade Download PDF

Info

Publication number
BR112013028776B1
BR112013028776B1 BR112013028776-4A BR112013028776A BR112013028776B1 BR 112013028776 B1 BR112013028776 B1 BR 112013028776B1 BR 112013028776 A BR112013028776 A BR 112013028776A BR 112013028776 B1 BR112013028776 B1 BR 112013028776B1
Authority
BR
Brazil
Prior art keywords
pterostilbene
anxiolytic
doses
anxiety
epm
Prior art date
Application number
BR112013028776-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013028776A2 (pt
Inventor
Agnes M. Rimando
Abir El-Aify
Md Al Rahim
Original Assignee
The United States of America, as represented by the Secretary of Agricuture
University Of Mississipi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States of America, as represented by the Secretary of Agricuture, University Of Mississipi filed Critical The United States of America, as represented by the Secretary of Agricuture
Publication of BR112013028776A2 publication Critical patent/BR112013028776A2/pt
Publication of BR112013028776B1 publication Critical patent/BR112013028776B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013028776-4A 2011-05-11 2012-05-10 Pteroestilbeno para uso no alívio ou prevenção da ansiedade BR112013028776B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/105,470 US9439875B2 (en) 2011-05-11 2011-05-11 Anxiolytic effect of pterostilbene
US13/105,470 2011-05-11
PCT/US2012/037325 WO2012154956A2 (en) 2011-05-11 2012-05-10 Anxiolytic effect of pterostilbene

Publications (2)

Publication Number Publication Date
BR112013028776A2 BR112013028776A2 (pt) 2017-01-24
BR112013028776B1 true BR112013028776B1 (pt) 2022-04-19

Family

ID=47140003

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028776-4A BR112013028776B1 (pt) 2011-05-11 2012-05-10 Pteroestilbeno para uso no alívio ou prevenção da ansiedade

Country Status (9)

Country Link
US (1) US9439875B2 (https=)
EP (1) EP2706992B1 (https=)
JP (2) JP6027607B2 (https=)
KR (1) KR101929074B1 (https=)
CN (1) CN103561729B (https=)
AU (1) AU2012253479B2 (https=)
BR (1) BR112013028776B1 (https=)
CA (1) CA2839309C (https=)
WO (1) WO2012154956A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene
ES2649730T3 (es) 2013-03-15 2018-01-15 Glia Llc Distribución craneal de compuestos farmacéuticos
CN103333141B (zh) * 2013-06-05 2015-04-29 宁波大学 一种白藜芦醇低聚茋类化合物及其制备方法和应用
JP6406865B2 (ja) * 2014-04-25 2018-10-17 森永製菓株式会社 濃度測定方法
JP6463956B2 (ja) * 2014-11-28 2019-02-06 キユーピー株式会社 乳化組成物及びその製造方法
CN104706627A (zh) * 2015-03-12 2015-06-17 厦门大学 一种治疗缺血性脑中风的药物
WO2017011318A1 (en) 2015-07-10 2017-01-19 University Of Miami Methods for treating mucopolysaccharidosis
EP3500267A4 (en) 2016-08-22 2020-03-18 Elysium Health, Inc. NICOTINAMIDRIBOSIDE AND PTEROSTILLE COMPOSITIONS AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES
WO2018213715A1 (en) * 2017-05-18 2018-11-22 Elysium Health, Inc. Methods and compositions for improving sleep
JP6619108B2 (ja) * 2019-01-07 2019-12-11 キユーピー株式会社 乳化組成物及びその製造方法
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
CN110075094A (zh) * 2019-02-27 2019-08-02 延边大学 紫檀芪在制备药物或保健品中的应用
CN112618520A (zh) * 2021-01-14 2021-04-09 姚大纯 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020999A2 (en) * 2004-08-19 2006-02-23 The United States Of America, As Represented By The Secretary Of Agriculture Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform
US20060216331A1 (en) * 2005-02-28 2006-09-28 Lines Thomas C Composition for treating mental health disorders
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US20090163580A1 (en) * 2007-12-24 2009-06-25 Natrol, Inc. Anti-aging composition containing resveratrol and method of administration
JP5526762B2 (ja) * 2009-02-17 2014-06-18 Ｊｎｃ株式会社 誘電率異方性が負の液晶性化合物、これを用いた液晶組成物および液晶表示素子
WO2010095926A1 (en) 2009-02-20 2010-08-26 N.V. Nutricia Use of reveratrol for preserving cognitive functioning
US9737495B2 (en) * 2009-06-22 2017-08-22 Indus Biotech Private Limited Process for obtaining purified pterostilbene and methods of use thereof
EP2322159A1 (en) * 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
US9439875B2 (en) * 2011-05-11 2016-09-13 The United States Of America, As Represented By The Secretary Of Agriculture Anxiolytic effect of pterostilbene

Also Published As

Publication number Publication date
KR20140107112A (ko) 2014-09-04
CN103561729A (zh) 2014-02-05
EP2706992B1 (en) 2019-09-04
EP2706992A4 (en) 2014-12-17
HK1194302A1 (zh) 2014-10-17
WO2012154956A2 (en) 2012-11-15
KR101929074B1 (ko) 2018-12-13
WO2012154956A3 (en) 2013-01-24
US20160067192A1 (en) 2016-03-10
BR112013028776A2 (pt) 2017-01-24
CA2839309C (en) 2019-05-07
EP2706992A2 (en) 2014-03-19
CA2839309A1 (en) 2012-11-15
US9439875B2 (en) 2016-09-13
JP6027607B2 (ja) 2016-11-16
AU2012253479A1 (en) 2013-11-28
JP2017014284A (ja) 2017-01-19
CN103561729B (zh) 2016-03-09
JP2014514361A (ja) 2014-06-19
AU2012253479B2 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
BR112013028776B1 (pt) Pteroestilbeno para uso no alívio ou prevenção da ansiedade
RU2563991C2 (ru) Синергические комбинации каротиноидов и полифенолов
US20100168112A1 (en) 2-Substituted and 4-substituted aryl nitrone compounds
BR122019001241B1 (pt) Método de purificação de canabinoides
JP2022523864A (ja) ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法
BR112020024164B1 (pt) Inibidores potentes de d-aminoácido oxidase (daao) e seu método de produção
BR112016005509B1 (pt) uso de uma composição
BR112020010089A2 (pt) compostos inéditos como inibidores de mpges-1
TW201618802A (zh) 用於調控ｐｐ２ａ甲基化反應並提供抗氧化及抗發炎活性之天然萃取物
ES2886345T3 (es) Métodos y composiciones para el tratamiento de enfermedades vasculares arterioescleróticas
HK1194302B (en) Use of pterostilbene for the manufacture of a pharmaceutical composition for the treatment, alleviation, or prevention of anxiety
CN115006346B (zh) 精神疾病治疗剂的稳定化方法和包含阿米替林的组合物
US12534439B2 (en) Xanthohumol derivatives and methods for making and using
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
BR112021003147A2 (pt) complexo de zinco, produção e uso do mesmo
US20230255961A1 (en) Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones
US20250161241A1 (en) Cysteamides, therapeutic compositions thereof, and related methods
CN121221580A (zh) 富马酸二甲酯在制备治疗高甘油三酯血症性急性胰腺炎药物中的应用
CN118742304A (zh) 用于神经退行性疾病的化合物和组合物
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas
CN102895222A (zh) 5-(3,4-亚甲二氧基苯基)-2e,4e戊二稀酸正丙胺酰胺在制备治疗神经疾病产品中的应用
BR122024013534A2 (pt) Sais e cocristais farmaceuticamente aceitáveis de sepiapterina, composição farmacêutica compreendendo os mesmos, e seus usos
US20130296441A1 (en) Anti-Obesity Properties of Pterostilbene
BR112020003865A2 (pt) composições farmacêuticas compreendendo sepiapterina e seus usos
CN102091105A (zh) 败酱草及其制剂的新用途

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/05/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2826 DE 06-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.